查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858091

多形性膠質母細胞瘤治療市場按治療類型、藥物類別、治療線、最終用戶和分銷管道分類 - 全球預測 2025-2032

Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line Of Therapy, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多形性膠質母細胞瘤治療市場將成長至 64.1 億美元，複合年成長率為 8.38%。

關鍵市場統計數據
基準年 2024 33.6億美元
預計年份：2025年 36.5億美元
預測年份 2032 64.1億美元
複合年成長率 (%) 8.38%

對多形性膠質母細胞瘤治療格局進行策略概述，重點在於臨床挑戰、創新動能和相關人員的需求。

多形性膠質母細胞瘤仍是神經腫瘤學領域最棘手的臨床挑戰之一，其特徵是腫瘤生物學特性具有侵襲性、分子異質性，且難以獲得持久的治療反應。基因組分析、免疫腫瘤學和標靶藥物的進步為治療性介入介入開闢了新的途徑，但臨床治療仍需要神經外科、放射腫瘤科、內科腫瘤科和支持治療團隊之間精細的協調。因此，研究、臨床治療和商業化領域的相關人員必須權衡近期治療需求與對有望提高生存率和生活品質的技術創新進行長期投資之間的關係。

本執行摘要概述了當前的治療格局，重點介紹了研發和商業化策略的關鍵轉變，並組裝了領導者可以採取哪些切實可行的措施來協調產品線、夥伴關係和患者准入計劃。本書著重於轉化醫學的優先事項、營運韌性和以病人為中心的交付模式，幫助決策者應對複雜的監管環境、供應鏈的波動以及不斷變化的醫保報銷機制，同時始終關注臨床療效和價值創造。

精準醫療的突破、免疫療法的進步以及多學科整合模式正在推動變革性轉變，再形成膠質母細胞瘤的治療方式。

在精準醫療、免疫療法和整合式醫療服務的推動下，膠質母細胞瘤的治療模式正在發生顯著變革時期。分子分型和先進的定序正在改變臨床治療思路，使其從「一刀切」的治療模式轉向以生物標記主導的治療，從而靶向特定的致癌促進要素和腫瘤微環境特徵。同時，免疫療法，例如查核點抑制劑和疫苗平台，正進入後期臨床試驗和聯合治療策略階段，促使人們重新評估治療順序和患者選擇標準。

同時，外科手術技術、立體定位放射放射線手術和放射治療計劃的改進正在增強局部控制方法，並為協同組合方案創造了機會。這些臨床進展得到了法律規範的支持，該框架日益認知到需要採用適應性試驗設計和真實世界證據來評估效用在罕見和異質性適應症中的療效。總而言之，這些轉變要求臨床團隊、臨床試驗設計者和商業領導者跨學科合作，以加速新興療法從實驗室到臨床的轉化，同時確保患者公平地獲得治療。

評估美國貿易政策和關稅調整對膠質母細胞瘤治療供應鏈和創新網路的累積影響

美國貿易政策和關稅政策的演變可能會影響神經膠母細胞瘤的治療生態系統，具體表現在成本結構、關鍵投入品的供應以及跨境合作的運作流程等方面。活性藥物原料藥、生技藥品製劑或專用設備的關稅調整可能會增加製造商和醫療系統的採購成本，這可能會改變其籌資策略，並促使其進行資源配置或供應商多元化。如果再加上試劑和設備交貨前置作業時間延長等上游因素的影響，這些壓力可能會使臨床試驗的物流更加複雜，並延遲多國試驗的啟動或擴展。

除了純粹的成本影響之外，政策主導的貿易動態可能會改變合作和授權模式。企業可能會加快對區域製造的投資，或尋求其他監管途徑以降低關稅波動帶來的風險。這可能既帶來挑戰，也帶來機會。雖然短期中斷可能會增加營運複雜性，但也可能刺激對國內生產能力、區域供應中心和更具韌性的採購路徑的投資。供應鏈透明度和對雙重採購的重視對於創新生態系統至關重要，相關人員應積極評估合約條款、庫存策略和合作生產協議，以確保研究項目的連續性和患者獲得治療的機會。

細分市場分析揭示了治療類型、藥物類別、治療線、最終用戶和分銷管道如何影響臨床策略和商業化。

細緻的細分視角揭示了治療創新如何與臨床實踐、支付方預期和分銷現實相互交織。按治療類型分類，主要類別包括藥物治療、放射線治療、支持性治療和手術。藥物治療包括化療、基因治療、免疫治療和標靶治療等個人化治療方法。化療藥物包括Carmustine、合併化療和Temozolomide等。基因治療再細分為基因編輯療法和溶瘤病毒療法。免疫治療分為查核點抑制劑和疫苗，標靶治療包括Bevacizumab和EGFR抑制劑。放射線治療包括近距離放射治療、體外放射線治療和放射線手術。支持性治療包括抗癲癇藥物和皮質類固醇。手術介入的範圍從切片檢查到開顱手術。

依藥物類別分類，烷化劑（如Carmustine和PembrolizumabTemozolomide）仍然是基石，而免疫查核點抑制劑（如Nivolumab和帕博利珠單抗）、單株抗體（如貝伐珠單抗）、溶瘤病毒療法（如西替莫基因）以及包括樹突狀細胞疫苗和胜肽疫苗在內的疫苗平台完善了治療方案。治療線細分區分第一線、二線和三線療法，每種療法都有不同的臨床終點、耐受性優先考慮因素和證據閾值。最終用戶涵蓋家庭醫療保健、一線、研究機構和專科診所，分銷管道涵蓋醫院藥房、線上藥房和零售藥房。這些細分結合起來，為評估臨床效用、研發風險和商業性路徑提供了一個結構化的框架，使相關人員能夠設定符合實際醫療服務模式的投資目標、試驗設計和上市策略。

亞太、歐洲、中東和非洲的區域動態正在影響醫療服務取得、監管重點和醫療服務模式。

區域差異對膠質母細胞瘤療法的研發、核准和應用有著至關重要的影響。在美洲，先進的臨床試驗基礎設施、專業的癌症中心和完善的醫保報銷機制共同促進了新型療法的快速應用，但支付方的監管和預算考慮在商業化規劃中仍然發揮著重要作用。在歐洲、中東和非洲，不同的監管路徑、神經外科專科中心資源的差異以及衛生技術評估時間線的顯著差異，共同造就了複雜的市場環境，並影響藥物的實施和定價策略。亞太地區的特點是臨床研究能力的快速發展、政府對本土生產的大力支持、精準腫瘤學能力的持續投入。這些因素共同為區域夥伴關係和在地化的打入市場策略創造了蓬勃發展的機會。

這些地區的監管細則、報銷方式和醫療服務模式差異顯著，因此製造商和醫療系統需要相應地調整其臨床證據產生和准入計劃。跨區域合作、技術轉移安排和量身定做的患者支援可以彌合醫療服務方面的差距。透過將臨床開發計劃與區域監管要求和醫療服務基礎設施相協調，相關人員可以在控制營運和商業風險的同時，提高患者及時獲得治療的可能性。

競爭格局：重點在於研發重點、臨床管線差異化、合作以及生產製造優先事項，這些因素共同塑造了膠質母細胞瘤治療藥物的研發過程。

膠質母細胞瘤領域的企業策略日益依賴差異化的研發組合、有針對性的合作以及規劃好的生產佈局。主要企業正優先進行強力的轉化項目，以檢驗生物標記、最佳化組合方案並產生機制證據，從而支持監管申報和與支付方的溝通。臨床研發管線涵蓋了多種後期免疫療法、針對可靶向突變的標靶藥物以及旨在提高中樞神經系統滲透性的創新遞送技術。為了保持競爭優勢，各公司正投資於適應性試驗設計、籃子試驗和真實世界證據的生成，以加速適應症拓展並為醫保報銷申請提供依據。

生物製藥公司、學術中心和受託製造廠商之間的夥伴關係正變得日益戰略化，許多公司尋求共同開發安排，以共用臨床風險並獲得細胞和基因療法的專業生產資源。需要考慮的因素包括地域容量、品質系統和供應鏈冗餘，尤其是在複雜生物製藥和病毒載體的生產方面。在商業性，早期與臨床醫生、支付方和患者權益組織合作的公司在簡化產品推廣方面具有優勢，而投資於數據基礎設施和結果指標的公司則在向支付方和整個醫療保健系統證明其價值方面具有優勢。

為行業領導者提供切實可行的建議，以加速轉化研究、最佳化臨床路徑並增強以患者為中心的醫療服務可及性。

行業領導者應優先採取一系列切實可行的措施，以加速轉化醫學進程並改善患者可及性。首先，研發投資應集中於高價值的轉化路徑，以檢驗生物標記和聯合治療策略，從而提高臨床成功率並促進法規核准。其次，應採用靈活的試驗架構和可操作的終點指標，兼顧科學嚴謹性和可行性，從而提高患者招募效率，並在異質人群中清晰地檢測到訊號。第三，應加強臨床營運、法規事務、生產製造和商業團隊之間的跨職能協作，確保研發項目從早期階段就考慮到醫保報銷和供應鏈的實際情況。

同時，領導者應加強以患者為中心的醫療服務獲取策略，投資於中心輻射式醫療模式、用於監測和依從性的數位化健康工具，以及旨在減少治療啟動和持續性障礙的客製化支持計畫。風險緩解措施，例如雙重採購、緊急庫存計劃和合約保護，可以確保臨床實驗和商業供應的連續性。最後，與學術中心、專科診所和第三方製造商建立策略夥伴關係，可以加速能力建設，同時分散專案風險，使機構能夠快速回應臨床機會和政策變化。

調查方法概述了膠質母細胞瘤研究的主要和次要研究資料收集、專家參與以及分析框架。

本分析的方法論結合了專家臨床醫生、臨床實驗研究人員、製造商和患者權益倡導者的定性訪談，以及整契約行評審文獻、臨床試驗註冊資訊和監管指南的結構化二手研究。專家訪談提供了關於臨床實踐差異、臨床試驗設計權衡和真實世界治療路徑的背景資訊，而二手資訊則用於對治療機制、安全性特徵和比較療法的療效進行三角驗證。分析架構包括跨領域分析、產品線優先排序矩陣和情境規劃，以評估不同政策和供應鏈條件下的營運和商業性影響。

這種方法兼顧了深度和廣度。初步調查確保了基於當前實踐的洞見，並捕捉了新興的臨床趨勢；而系統的二次綜合分析則提供了可複製的依證。在適當情況下，分析會納入對採購和監管環境的結構化敏感度分析，重點相關人員的應對措施和策略性緊急計畫。

總結性綜述將臨床現實、政策影響和創新機會聯繫起來，以指導下一步的研究、護理和商業性成功。

總之，膠質母細胞瘤治療領域正處於快速科學進展與持續臨床複雜性的交會點。分子診斷、免疫療法合併治療和局部控制技術的進步為改善患者預後提供了實際的機會。然而，包括貿易因素和區域監管差異在內的政策和供應鏈動態，增加了營運的複雜性，必須積極主動地加以管理，以保障臨床試驗的連續性和患者的治療機會。

展望未來，將轉化優先事項與切實可行的營運計劃相結合的相關人員，將更有利於把創新轉化為有意義的治療方案。跨部門合作、投資於具有韌性的供應鏈以及與支付方和監管機構持續對話，並專注於以患者為中心的治療結果和公平的醫療服務獲取，將加速高價值治療方法的推廣應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將腫瘤治療與個人化CAR-T細胞療法結合，以改善膠質母細胞瘤患者的預後
  • 標靶EGFRvIII和PD-1路徑雙特異性抗體在膠質母細胞瘤免疫治療的出現
  • 開發一種對流增強型遞送系統，用於精準地將藥物輸送穿過血腦障壁
  • 利用液態切片技術即時監測膠質母細胞瘤的治療反應和抗藥性
  • 增加對溶瘤病毒療法的投資，該療法旨在選擇性地靶向膠質母細胞瘤幹細胞群。
  • 腫瘤微環境調變器的臨床進展，可克服膠質母細胞瘤治療中的免疫抑制微環境

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 多形性膠質母細胞瘤治療市場依治療類型分類

  • 藥物治療
    • 化療
      • Carmustine
      • 合併化療
      • Temozolomide
    • 基因治療
      • 基因編輯
      • 溶瘤病毒療法
    • 免疫療法
      • 查核點抑制劑
      • 疫苗
    • 標靶治療
      • Bevacizumab
      • EGFR抑制劑
  • 放射線治療
    • 近距離放射治療
    • 放射治療
    • 放射線手術
  • 支持性護理
    • 抗癲癇藥物
    • 皮質類固醇
  • 外科手術
    • 切片檢查程序
    • 開顱手術

9. 多形性膠質母細胞瘤治療市場（依藥物類別分類）

  • 烷化劑
    • Carmustine
    • Temozolomide
  • 查核點抑制劑
    • Nivolumab
    • Pembrolizumab
  • 單株抗體
    • Bevacizumab
  • 溶瘤病毒療法
    • 希莫根·塞拉德諾瓦克
  • 疫苗療法
    • 樹突細胞疫苗
    • 胜肽疫苗

10. 多形性膠質母細胞瘤治療市場（依治療線分類）

  • 一線
  • 第二行
  • 三線

第11章 多形性膠質母細胞瘤治療市場（依最終用戶分類）

  • 家庭醫療保健
  • 醫院
  • 研究所
  • 專科診所

12. 多形性膠質母細胞瘤治療市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 多形性膠質母細胞瘤治療市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 多形性膠質母細胞瘤治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 多形性膠質母細胞瘤治療市場（依國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Novocure Ltd.
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Limited
    • Accord Healthcare Limited
    • Zydus Lifesciences Limited
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market is projected to grow by USD 6.41 billion at a CAGR of 8.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.36 billion
Estimated Year [2025] USD 3.65 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 8.38%

Strategic overview of glioblastoma multiforme treatment landscape highlighting clinical challenges, innovation momentum, and stakeholder imperatives

Glioblastoma multiforme remains one of the most formidable clinical challenges in neuro-oncology, defined by aggressive tumor biology, heterogeneity at the molecular level, and entrenched barriers to durable treatment response. Advances in genomic profiling, immuno-oncology, and targeted agents have created new avenues for therapeutic intervention, yet the clinical pathway still requires nuanced coordination among neurosurgery, radiation oncology, medical oncology, and supportive care teams. As a result, stakeholders across research, clinical care, and commercialization must balance near-term care delivery needs with long-term investments in innovation that promise improved survival and quality of life.

This executive summary synthesizes the current therapeutic landscape, highlights pivotal shifts in R&D and commercial strategy, and frames pragmatic actions that leaders can take to align pipelines, partnerships, and patient access programs. By concentrating on translational priorities, operational resilience, and patient-centric delivery models, the document prepares decision-makers to navigate regulatory complexity, supply chain volatility, and evolving reimbursement environments while maintaining focus on clinical outcomes and value creation.

Transformative shifts reshaping glioblastoma care driven by precision medicine breakthroughs, immunotherapy advances, and integrated multidisciplinary models

The glioblastoma treatment landscape is undergoing a period of substantive transformation driven by precision medicine, immunotherapy, and integrated care delivery. Molecular subtyping and advanced sequencing have shifted clinical thinking away from one-size-fits-all approaches toward biomarker-driven interventions that target specific oncogenic drivers or tumor microenvironment characteristics. Concurrently, immunotherapies, including checkpoint inhibitors and vaccine platforms, have moved into late-stage clinical testing and combination strategies, prompting a re-evaluation of therapeutic sequencing and patient selection criteria.

In parallel, improvements in surgical techniques, stereotactic radiosurgery, and radiotherapy planning have strengthened local control approaches and created opportunities for synergistic multimodal regimens. These clinical advances are supported by evolving regulatory frameworks that increasingly recognize the need for adaptive trial designs and real-world evidence to assess benefit in rare and heterogeneous indications. Taken together, these shifts demand that clinical teams, trial designers, and commercial leaders coordinate across disciplines to accelerate translation from bench to bedside while ensuring equitable patient access to emerging therapies.

Assessing the cumulative impact of United States trade policy and tariff adjustments on glioblastoma treatment supply chains and innovation networks

Evolving United States trade policy and tariff considerations can influence the glioblastoma treatment ecosystem by affecting the cost structure, availability of critical inputs, and the operational cadence of cross-border collaborations. Tariff adjustments on active pharmaceutical ingredients, biologics components, or specialized equipment have the potential to raise procurement costs for manufacturers and health systems, which may in turn shift sourcing strategies and prompt reshoring or supplier diversification. When combined with upstream effects such as increased lead times for reagents and devices, these pressures can complicate clinical trial logistics and slow the initiation or expansion of multinational studies.

Beyond pure cost impacts, policy-driven trade dynamics can alter patterns of partnership and licensing. Companies may accelerate in-region manufacturing investments or pursue alternative regulatory routes to mitigate exposure to tariff volatility. This can create both headwinds and opportunities: while near-term disruptions may increase operational complexity, they can also incentivize investments in domestic production capacity, regional supply hubs, and more resilient procurement pathways. For innovation ecosystems, an increased emphasis on supply chain transparency and dual sourcing will be essential, and stakeholders should proactively assess contract terms, inventory strategies, and collaborative manufacturing agreements to preserve continuity for research programs and patient treatment access.

Segmentation analysis revealing how treatment types, drug classes, therapy lines, end users, and distribution channels jointly inform clinical strategy and commercialization

A nuanced segmentation lens reveals where therapeutic innovation intersects with clinical practice, payer expectations, and distribution realities. When examined by treatment type, key categories include Drug Therapy, Radiotherapy, Supportive Care, and Surgical. Within Drug Therapy there are discrete modalities such as Chemotherapy, Gene Therapy, Immunotherapy, and Targeted Therapy; Chemotherapy itself encompasses agents like Carmustine, Combination Chemotherapy, and Temozolomide, while Gene Therapy subdivides into Gene Editing and Oncolytic Virus Therapy. Immunotherapy splits into Checkpoint Inhibitors and Vaccines, and Targeted Therapy includes agents such as Bevacizumab and EGFR Inhibitors. Radiotherapy covers Brachytherapy, External Beam Radiotherapy, and Radiosurgery, Supportive Care addresses Antiepileptic Drugs and Corticosteroids, and Surgical interventions range from Biopsy Procedures to Craniotomy.

Viewed through the prism of drug class, alkylating agents such as Carmustine and Temozolomide remain foundational, while checkpoint inhibitors represented by agents like Nivolumab and Pembrolizumab, monoclonal antibodies exemplified by Bevacizumab, oncolytic virus therapies such as sitimogene ceradenovac, and vaccine platforms including dendritic cell vaccines and peptide vaccines round out the therapeutic palette. Line-of-therapy segmentation differentiates First Line, Second Line, and Third Line approaches, each with distinct clinical endpoints, tolerability priorities, and evidence thresholds. End users span Home Healthcare, Hospitals, Research Institutes, and Specialty Clinics, and distribution channels move through Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Together, these segmentation dimensions provide a structured framework for assessing clinical utility, development risk, and commercial pathways, enabling stakeholders to target investments, design trials, and configure go-to-market strategies that map to real-world care delivery patterns.

Regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape access, regulatory priorities, and care delivery models

Regional variation exerts a decisive influence on how glioblastoma therapies are developed, approved, and delivered. In the Americas, a combination of advanced clinical trial infrastructure, centralized cancer centers, and established reimbursement mechanisms supports rapid adoption of novel therapeutics, though payer scrutiny and budget impact considerations remain influential in commercialization planning. Europe, the Middle East & Africa presents a heterogeneous picture with diverse regulatory pathways, variable access to specialized neurosurgical capabilities, and significant differences in health technology assessment timelines that affect uptake and pricing strategies. In Asia-Pacific, the landscape is characterized by fast-expanding clinical research capacity, strong government interest in domestic manufacturing, and growing investment in precision oncology capabilities that together create dynamic opportunities for regional partnerships and localized market entry strategies.

Regulatory nuance, reimbursement modalities, and healthcare delivery models differ materially across these regions, so manufacturers and health systems must calibrate clinical evidence generation and access programs accordingly. Cross-regional collaborations, technology transfer arrangements, and tailored patient support mechanisms can bridge gaps in care delivery. By aligning clinical development plans with regional regulatory expectations and delivery infrastructures, stakeholders can improve the likelihood of timely patient access while managing operational and commercial risk.

Competitive landscape spotlighting R&D focus, clinical pipeline differentiation, partnerships, and manufacturing priorities shaping glioblastoma therapy development

Company strategies in glioblastoma are increasingly defined by differentiated R&D portfolios, targeted partnerships, and deliberate manufacturing positioning. Leading organizations prioritize robust translational programs to validate biomarkers, optimize combination regimens, and generate mechanistic evidence that supports regulatory submissions and payer dialogue. Clinical pipelines show a mix of late-stage combination immunotherapies, targeted agents addressing actionable mutations, and innovative delivery technologies aimed at improving central nervous system penetration. To sustain competitive advantage, companies are investing in adaptive trial designs, basket studies, and real-world evidence generation that can accelerate label expansions and inform reimbursement dossiers.

Partnerships between biopharma, academic centers, and contract manufacturing organizations have grown more strategic, with many companies seeking co-development arrangements to share clinical risk and access specialized manufacturing for cell and gene therapies. Manufacturing considerations-particularly for complex biologics and viral vectors-drive decisions about geographic capacity, quality systems, and supply chain redundancy. Commercially, companies that integrate early engagement with clinicians, payers, and patient advocacy groups position themselves to streamline uptake, while those that invest in data infrastructure and outcomes measurement are better equipped to demonstrate value across payers and health systems.

Actionable recommendations for industry leaders to accelerate translational research, optimize clinical pathways, and strengthen patient-centric access

Industry leaders should prioritize a set of pragmatic actions that accelerate translational progress and improve patient access. First, align R&D investments to high-value translational pathways that validate biomarkers and combination strategies, thereby improving the probability of clinical success and facilitating regulatory engagement. Second, adopt flexible trial architectures and pragmatic endpoints that balance scientific rigor with operational feasibility, enabling more efficient patient enrollment and clearer signal detection across heterogeneous populations. Third, strengthen cross-functional collaborations among clinical operations, regulatory affairs, manufacturing, and commercial teams to ensure that development programs are informed by reimbursement and supply chain realities from inception.

In parallel, leaders should reinforce patient-centric access strategies by investing in hub-and-spoke care models, digital health tools for monitoring and adherence, and tailored support programs that reduce barriers to therapy initiation and continuation. Risk mitigation measures such as dual sourcing, contingency inventory planning, and contractual protections can preserve continuity for trials and commercial supply. Finally, strategic partnerships with academic centers, specialty clinics, and third-party manufacturers can accelerate capability building while distributing program risk, enabling organizations to respond quickly to clinical opportunities and policy shifts.

Research methodology outlining primary and secondary data collection, expert engagement, and analytical frameworks for glioblastoma insights

The methodology underpinning this analysis combines primary qualitative engagement with expert clinicians, trial investigators, manufacturers, and patient advocates alongside structured secondary research synthesizing peer-reviewed literature, clinical trial registries, and regulatory guidance. Expert interviews provided contextual nuance on clinical practice variation, trial design trade-offs, and real-world treatment pathways, while secondary sources were used to triangulate evidence on therapeutic mechanisms, safety profiles, and comparative modality performance. Analytical frameworks included cross-segmentation mapping, pipeline prioritization matrices, and scenario planning to evaluate operational and commercial implications under differing policy and supply chain conditions.

This approach balances depth and breadth: primary engagement ensures current, practice-based insights and captures emerging clinical sentiment, while systematic secondary synthesis provides a reproducible evidence base. Where appropriate, the analysis incorporates structured sensitivity around procurement and regulatory scenarios to highlight resilience levers and strategic contingencies that stakeholders can deploy in response to evolving external conditions.

Concluding synthesis that connects clinical realities, policy influences, and innovation opportunities to guide research, care, and commercial next steps

In conclusion, the glioblastoma treatment arena sits at the intersection of rapid scientific progress and persistent clinical complexity. Molecular diagnostics, immunotherapy combinations, and advances in local control techniques offer tangible opportunities to improve patient outcomes, yet translating these advances into consistent clinical benefit requires integrated strategy across development, manufacturing, and access functions. Policy and supply chain dynamics, including trade considerations and regional regulatory variability, add layers of operational complexity that must be proactively managed to protect trial continuity and patient access.

Moving forward, stakeholders who synchronize translational priorities with pragmatic operational plans will be best positioned to convert innovation into meaningful therapeutic options. Cross-sector collaboration, investments in resilient supply chains, and sustained dialogue with payers and regulatory authorities will accelerate adoption of high-value therapies while maintaining the focus on patient-centered outcomes and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of tumor-treating fields with personalized CAR T-cell therapies to improve glioblastoma patient outcomes
  • 5.2. Emergence of bispecific antibodies targeting EGFRvIII and PD-1 pathways in glioblastoma immunotherapy
  • 5.3. Development of convection-enhanced delivery systems for precision drug transport across the blood brain barrier
  • 5.4. Adoption of liquid biopsy techniques for real-time monitoring of glioblastoma treatment response and resistance
  • 5.5. Rising investment in oncolytic virus therapies engineered to selectively target glioblastoma stem cell populations
  • 5.6. Clinical advancement of tumor microenvironment modulators to overcome immunosuppressive niches in glioblastoma treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glioblastoma Multiforme Treatment Market, by Treatment Type

  • 8.1. Drug Therapy
    • 8.1.1. Chemotherapy
      • 8.1.1.1. Carmustine
      • 8.1.1.2. Combination Chemotherapy
      • 8.1.1.3. Temozolomide
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Gene Editing
      • 8.1.2.2. Oncolytic Virus Therapy
    • 8.1.3. Immunotherapy
      • 8.1.3.1. Checkpoint Inhibitors
      • 8.1.3.2. Vaccines
    • 8.1.4. Targeted Therapy
      • 8.1.4.1. Bevacizumab
      • 8.1.4.2. EGFR Inhibitors
  • 8.2. Radiotherapy
    • 8.2.1. Brachytherapy
    • 8.2.2. External Beam Radiotherapy
    • 8.2.3. Radiosurgery
  • 8.3. Supportive Care
    • 8.3.1. Antiepileptic Drugs
    • 8.3.2. Corticosteroids
  • 8.4. Surgical
    • 8.4.1. Biopsy Procedures
    • 8.4.2. Craniotomy

9. Glioblastoma Multiforme Treatment Market, by Drug Class

  • 9.1. Alkylating Agents
    • 9.1.1. Carmustine
    • 9.1.2. Temozolomide
  • 9.2. Checkpoint Inhibitors
    • 9.2.1. Nivolumab
    • 9.2.2. Pembrolizumab
  • 9.3. Monoclonal Antibodies
    • 9.3.1. Bevacizumab
  • 9.4. Oncolytic Virus Therapies
    • 9.4.1. Sitimogene Ceradenovac
  • 9.5. Vaccine Therapies
    • 9.5.1. Dendritic Cell Vaccines
    • 9.5.2. Peptide Vaccines

10. Glioblastoma Multiforme Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Glioblastoma Multiforme Treatment Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Glioblastoma Multiforme Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Glioblastoma Multiforme Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glioblastoma Multiforme Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glioblastoma Multiforme Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Novocure Ltd.
    • 16.3.4. Teva Pharmaceutical Industries Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Sandoz International GmbH
    • 16.3.7. Dr. Reddy's Laboratories Limited
    • 16.3.8. Accord Healthcare Limited
    • 16.3.9. Zydus Lifesciences Limited
    • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION